quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:13:27·342d
INSIDERFiling
ZoomInfo Technologies Inc logo

Director Gleeson Alison converted options into 15,187 shares, increasing direct ownership by 105% to 29,596 units (SEC Form 4)

ZI· ZoomInfo Technologies Inc
Technology
Original source

Companies

  • ZI
    ZoomInfo Technologies Inc
    Technology

Recent analyst ratings

  • Feb 26UpdatePiper Sandler$11.00
  • Jan 7UpdateWells Fargo$11.00
  • Jan 6UpdatePiper Sandler$10.00
  • Dec 13UpdateKeyBanc Capital Markets-
  • Nov 19UpdateScotiabank$10.30
  • Aug 13UpdateDaiwa Securities$9.00

Related

  • SEC324d
    SEC Form 144 filed by ZoomInfo Technologies Inc
  • INSIDER324d
    General Counsel and Corp Sec Mcgrane Ashley converted options into 1,317 shares, covered exercise/tax liability with 388 shares and sold $50,483 worth of shares (5,270 units at $9.58), decreasing direct ownership by 19% to 19,121 units (SEC Form 4)
  • INSIDER324d
    Large owner Hskb Funds Ii, Llc disposed of 13,945 shares, decreasing direct ownership by 3% to 493,216 units (SEC Form 4)
  • INSIDER324d
    Interim CFO O'Brien Michael Graham converted options into 1,288 shares and covered exercise/tax liability with 430 shares, increasing direct ownership by 2% to 48,078 units (SEC Form 4)
  • INSIDER324d
    Chief Revenue Officer Roth James M converted options into 1,353 shares and covered exercise/tax liability with 665 shares, increasing direct ownership by 2% to 44,511 units (SEC Form 4)
  • INSIDER339d
    SEC Form 4 filed by Chief Revenue Officer Roth James M
  • INSIDER339d
    SEC Form 4 filed by Interim CFO O'Brien Michael Graham
  • INSIDER342d
    Director Rooney Katie J. converted options into 5,539 shares (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022